We are live on ! Find out more
AVXL icon

Anavex Life Sciences

153 hedge funds and large institutions have $245M invested in Anavex Life Sciences in 2023 Q4 according to their latest regulatory filings, with 27 funds opening new positions, 56 increasing their positions, 36 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

59% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 17

56% more repeat investments, than reductions

Existing positions increased: 56 | Existing positions reduced: 36

49% more capital invested

Capital invested by funds: $164M → $245M (+$80.9M)

7% more funds holding

Funds holding: 143153 (+10)

1.49% more ownership

Funds ownership: 30.58%32.07% (+1.5%)

47% less call options, than puts

Call options by funds: $11.6M | Put options by funds: $21.9M

Holders
153
Holders Change
+10
Holders Change %
+6.99%
% of All Funds
2.23%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
27
Increased
56
Reduced
36
Closed
17
Calls
$11.6M
Puts
$21.9M
Net Calls
-$10.3M
Net Calls Change
-$13.7M
Name Holding Trade Value Shares
Change
Change in
Stake
CS
26
Credit Suisse
Switzerland
$907K +$1.79K +260 +0.3%
UBS AM
27
UBS AM
Illinois
$902K
Commonwealth Equity Services
28
Commonwealth Equity Services
Massachusetts
$855K +$58.9K +8,557 +10%
AllianceBernstein
29
AllianceBernstein
Tennessee
$820K +$34.4K +5,000 +6%
HP
30
Hikari Power
Japan
$797K
California State Teachers Retirement System (CalSTRS)
31
California State Teachers Retirement System (CalSTRS)
California
$790K -$15.7K -2,284 -3%
CIC
32
Carnegie Investment Counsel
Ohio
$686K +$43K +6,250 +9%
Simplex Trading
33
Simplex Trading
Illinois
$671K +$497K +72,136 New
Legal & General Group
34
Legal & General Group
United Kingdom
$664K -$1.38K -201 -0.3%
Balyasny Asset Management
35
Balyasny Asset Management
Illinois
$645K +$303K +44,030 +174%
Wells Fargo
36
Wells Fargo
California
$634K -$300K -43,535 -39%
GWM
37
Geneos Wealth Management
Colorado
$629K +$176K +25,500 +61%
JP Morgan Chase
38
JP Morgan Chase
New York
$600K +$2.42K +352 +0.5%
JF
39
Jump Financial
Illinois
$568K -$99.2K -14,406 -19%
CAN
40
Cetera Advisor Networks
California
$555K -$63.4K -9,212 -13%
LPL Financial
41
LPL Financial
California
$548K +$20.2K +2,940 +5%
Los Angeles Capital Management
42
Los Angeles Capital Management
California
$541K +$261K +37,867 +187%
TI
43
Trexquant Investment
Connecticut
$537K +$397K +57,655 New
AA
44
ALPS Advisors
Colorado
$523K -$29.7K -4,320 -7%
Ameriprise
45
Ameriprise
Minnesota
$509K +$126K +18,277 +50%
AWM
46
AllSquare Wealth Management
New York
$498K -$10.3K -1,500 -3%
D.E. Shaw & Co
47
D.E. Shaw & Co
New York
$498K +$144K +20,913 +64%
CSS
48
Cubist Systematic Strategies
Connecticut
$475K +$351K +50,993 New
T. Rowe Price Associates
49
T. Rowe Price Associates
Maryland
$474K +$9.08K +1,319 +3%
Dimensional Fund Advisors
50
Dimensional Fund Advisors
Texas
$462K +$341K +49,596 New

AVXL Hedge Fund Activity: Q4 2023 in Review

153 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Anavex Life Sciences (AVXL) for Q4 2023, worth a combined $245M — up 49% from $164M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new AVXL positions and 17 closed out — a net gain of 10 holders — while 56 added to existing stakes and 36 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $4.35M. The largest seller was Millennium Management, cutting an estimated $4.8M.

  • 153 institutional investors held Anavex Life Sciences (AVXL) as of Q4 2023, up from 143 in Q3 2023.
  • Funds reported $245M of Anavex Life Sciences stock for Q4 2023, up 49% quarter-over-quarter.
  • 27 funds opened new Anavex Life Sciences positions in Q4 2023 and 17 closed out, a net change of +10 holders.
  • The largest Anavex Life Sciences buyer in Q4 2023 was Morgan Stanley, an estimated $4.35M added.
  • The largest Anavex Life Sciences seller in Q4 2023 was Millennium Management, an estimated $4.8M sold.

Based on aggregated 13F filings for Q4 2023.